Larvol Delta - ASLAN-Pharmaceuticals-to-Host-KOL-Panel-Discussion-on-Treatment-Options-for-Atopic-Dermatitis-Patients-With-an-Inadequate-Response-to-Dupilumab

eblasakimab (ASLAN004) - ASLAN Pharma, Zenyaku Holdings

https://www.globenewswire.com/news-release/2024/04/30/2872039/0/en/ASLAN-Pharmaceuticals-to-Host-KOL-Panel-Discussion-on-Treatment-Options-for-Atopic-Dermatitis-Patients-With-an-Inadequate-Response-to-Dupilumab.html

Apr 30, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next